IL132972A0 - Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders - Google Patents

Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Info

Publication number
IL132972A0
IL132972A0 IL13297299A IL13297299A IL132972A0 IL 132972 A0 IL132972 A0 IL 132972A0 IL 13297299 A IL13297299 A IL 13297299A IL 13297299 A IL13297299 A IL 13297299A IL 132972 A0 IL132972 A0 IL 132972A0
Authority
IL
Israel
Prior art keywords
acetylcholinesterase
muscular
treatment
pharmaceutical compositions
neuromuscular disorders
Prior art date
Application number
IL13297299A
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL13297299A priority Critical patent/IL132972A0/en
Priority to AU15461/01A priority patent/AU1546101A/en
Priority to PCT/IL2000/000763 priority patent/WO2001036627A2/en
Publication of IL132972A0 publication Critical patent/IL132972A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13297299A 1999-11-16 1999-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders IL132972A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL13297299A IL132972A0 (en) 1999-11-16 1999-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
AU15461/01A AU1546101A (en) 1999-11-16 2000-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
PCT/IL2000/000763 WO2001036627A2 (en) 1999-11-16 2000-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13297299A IL132972A0 (en) 1999-11-16 1999-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Publications (1)

Publication Number Publication Date
IL132972A0 true IL132972A0 (en) 2001-03-19

Family

ID=11073493

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13297299A IL132972A0 (en) 1999-11-16 1999-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Country Status (3)

Country Link
AU (1) AU1546101A (en)
IL (1) IL132972A0 (en)
WO (1) WO2001036627A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143379A (en) 2001-05-24 2013-11-28 Yissum Res Dev Co Antisense oligonucleotide against the r isophorm of human ache and uses thereof
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
EA201492116A1 (en) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492121A1 (en) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE FAMILY OF HEMOGLOBIN GENES
CA2873766A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating atp2a2 expression
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
AU2020275776A1 (en) * 2019-05-13 2021-12-09 The Trustees Of The University Of Pennsylvania Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5932780A (en) * 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
WO1998026062A2 (en) * 1996-12-12 1998-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2001036627A2 (en) 2001-05-25
WO2001036627A3 (en) 2001-10-04
AU1546101A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0103839A3 (en) Use of certain drugs for treating nerve root injury
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
HK1046240A1 (en) Pharmaceutical compositions for the treatment of insulin resistance
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
IL139591A0 (en) Combination therapy for treatment of bipolar disorders
MXPA02001790A (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation.
HUP0200275A3 (en) Seed treatment composition and preparation thereof
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
IL132972A0 (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
HUP0103832A3 (en) Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof
HUP0102436A3 (en) Use of reboxetin for preparation of medicament for nervous disorders
GB9926968D0 (en) Treatment of neurological disorders
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
GB0023304D0 (en) Skin treatment compositions
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
GB9906808D0 (en) Formulation for treatment of pain
GB9904252D0 (en) Composition for the treatment of pain
IL150202A0 (en) Method and composition for the treatment of pain
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
AU747073C (en) Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of medicament for the treatment of pain